Results 31 to 40 of about 1,338,680 (315)

What’s So Hard about Improving Access to Water and Sanitation?

, 2016
The World Bank is committed to ending extreme poverty and boosting shared prosperity. Providing clean, safe water to people wherever they live is critical to achieving these goals.
World Bank
core   +1 more source

Emulating RCT Using Asian RWD: LEADER

, 2022
With the growing amount of clinical evidence derived from large-scale Asian real world data (RWD) and interest in its use in regulatory decision-making, there is a strong need to evaluate the agreement between randomized controlled trials (RCTs) and real
Sohee Park, Ahhyung Choi, Hwa Yeon Ko, Ju-Young Shin, Han Eol Jeong   +4 more
core   +1 more source

Impact of "time zero" of Follow-Up Settings in a Comparative Effectiveness Study Using Real-World Data with a Non-user Comparator: Comparison of Six Different Settings

Drugs - Real World Outcomes, 2022
Background Time-related bias can lead to misleading conclusions. Properly setting the "time zero" of follow-up is crucial for avoiding these biases. However, the time-zero setting is challenging when comparing users and non-users of a study drug because ...
Ryozo Wakabayashi, Takahiro Hirano, Thomas Laurent, Yoshiki Kuwatsuru, Ryohei Kuwatsuru   +4 more
doaj   +1 more source

Real-world treatment patterns and outcomes among individuals receiving first-line pembrolizumab therapy for recurrent/metastatic head and neck squamous cell carcinoma

Frontiers in Oncology, 2023
BackgroundPembrolizumab, a PD-1 immune checkpoint inhibitor, is approved as first-line (1L) treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) as monotherapy or in combination with platinum and 5-fluorouracil ...
Christopher M. Black, Glenn J. Hanna, Liya Wang, Karthik Ramakrishnan, Daisuke Goto, Vladimir Turzhitsky, Gleicy M. Hair   +6 more
doaj   +1 more source

Real-World Evidence Analysis of a Hybrid Closed-Loop System. [PDF]

BACKGROUND We analyzed real-world evidence to assess the performance of the mylife CamAPS FX hybrid closed-loop system. METHODS Users from 15 countries across different age groups who used the system between May 9, 2022, and December 3, 2022 ...
Hovorka, Roman, Ruan, Yue, Wilinska, Malgorzata E, Alwan, Heba, Da Silva, Julien   +4 more
core   +1 more source

Health-related quality of life burden of nonalcoholic steatohepatitis: a robust pragmatic literature review

Journal of Patient-Reported Outcomes, 2018
Objective Nonalcoholic steatohepatitis (NASH) is a form of chronic liver disease (CLD): patients have an increased risk of developing cirrhosis, liver failure, and complications (e.g. hepatocellular carcinoma). NASH has a high clinical burden, and likely
Tessa Kennedy-Martin, Jay P. Bae, Rosirene Paczkowski, Emily Freeman   +3 more
doaj   +1 more source

Evaluating the Performance of High-Dimensional Propensity Scores Compared with Standard Propensity Scores for Comparing Antihypertensive Therapies in the CPRD GOLD Database

Cardiology and Therapy, 2023
Introduction Propensity score (PS) matching is widely used in medical record studies to create balanced treatment groups, but relies on prior knowledge of confounding factors.
Virginie Simon, Jade Vadel
doaj   +1 more source

Correlation Between Early Time-to-Event Outcomes and Overall Survival in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Receiving Definitive Chemoradiation Therapy: Systematic Review and Meta-Analysis

Frontiers in Oncology, 2022
BackgroundOverall survival (OS) is the most patient-relevant outcome in oncology; however, in early cancers, large sample sizes and extended follow-up durations are needed to detect statistically significant differences in OS between interventions.
Christopher M. Black, Sam Keeping, Ali Mojebi, Karthik Ramakrishnan, Diana Chirovsky, Navneet Upadhyay, Dylan Maciel, Dieter Ayers   +7 more
doaj   +1 more source

Treatment pathways, economic burden and clinical outcomes in new users of inhaled corticosteroid/long-acting B2-agonist dual therapy with chronic obstructive pulmonary disease in a primary care setting in England: a retrospective cohort study

BMJ Open
Objective Management of chronic obstructive pulmonary disease (COPD) with inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) improves lung function and health status and reduces COPD exacerbation risk versus monotherapy.
Victoria Banks, Robert Wood, Gema Requena, Alexandrosz Czira, Theo Tritton, Rosie Wild, Chris Compton, Afisi Ismaila   +7 more
doaj   +1 more source

Health‐Related Quality of Life and Symptom Severity Among Patients With PIK3CA‐Related Overgrowth Spectrum: A Mixed‐Methods Study to Understand Real‐World Experience With Alpelisib Treatment

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background PIK3CA‐related overgrowth spectrum (PROS) includes several rare overgrowth disorders resulting from somatic gain‐of‐function mutations in PIK3CA. Despite treatment advances, including the recent approval of alpelisib for PROS in the United States, literature detailing the patient experience with PROS is limited.
Vamsi Bollu, Kaitlin LaGasse, Cory D. Saucier, Kimberly Raymond, Miranda Lauher‐Charest, Lauren Crowder, Beilei Cai, Mary Lisha Paul, Denise Adams   +8 more
wiley   +1 more source